Image 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Image 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Table 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Image 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Image 8_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Image 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Table 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Table 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Table 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Table 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Image 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Table 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Table 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Image 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Image 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Data Sheet 1_Early coronary angiography in patients with myocardial infarction without ST elevation after out-of-hospital cardiac arrest: a systematic review and meta-analysis.pdf حسب Warda Ahmed (5593586)

"…Meta-regression explored factors modifying effect sizes.</p>Results<p>We identified 16 studies (7 RCTs, 9 observational studies) involving 4,737 patients. …"

Numerical data underlying the graphs. حسب Stephanie M. E. Jones (12883691)

"…MITF and c-MYC, key melanoma transcription factors, regulate human <i>DANCR</i> expression and melanoma patients with high <i>DANCR</i> display significantly decreased survival. …"

Sequence of oligonucleotides used in this study. حسب Stephanie M. E. Jones (12883691)

"…MITF and c-MYC, key melanoma transcription factors, regulate human <i>DANCR</i> expression and melanoma patients with high <i>DANCR</i> display significantly decreased survival. …"

Table 1_Supplementation of Yupingfeng polysaccharides in low fishmeal diets enhances intestinal health through influencing the intestinal barrier, immunity, and microflora in Macro... حسب Mingyang Liu (426690)

"…</p>Results<p>The LF diet significantly reduced growth performance parameters compared to the control group. …"

<i>DANCR</i> regulated genes in SK-MEL-28 cells. حسب Stephanie M. E. Jones (12883691)

"…MITF and c-MYC, key melanoma transcription factors, regulate human <i>DANCR</i> expression and melanoma patients with high <i>DANCR</i> display significantly decreased survival. …"